Reports Q4 revenue $10.7M, consensus $14.77M. “Mersana’s unwavering commitment to payload and platform innovation has enabled us to enter 2024 with differentiated clinical-stage ADC product candidates, a strong balance sheet and forward momentum,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics. “We have made progress in the dose escalation portion of our Phase 1 clinical trial of XMT-1660 while also enrolling patients in backfill cohorts at multiple clinically relevant dose levels, setting the stage for our planned initial clinical data disclosure for this candidate in mid-2024. Over the course of this year, we also look forward to advancing dose escalation in our Phase 1 clinical trial of XMT-2056 as well as our collaborations with Johnson & Johnson and Merck KGaA.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRSN:
- Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Mersana Therapeutics (MRSN) Q4 Earnings Cheat Sheet
- Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
- Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference